CLAIMS

1. Use of (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a disease or condition selected from diabetic neuropathy and trigeminal neuralgia in a subject, wherein the subject is not receiving treatment with a UGT inhibitor and prior to receiving the medicament, the subject either:

a) is receiving treatment with a UGT inhibitor and the subject is instructed to discontinue treatment with the UGT inhibitor prior to receiving the medicament; or

b) is not receiving treatment with a UGT inhibitor and the subject is instructed not to commence treatment with the UGT inhibitor prior to receiving the medicament; and

the medicament is for administration of the (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or the pharmaceutically acceptable salt thereof, at a dosage of 200 mg two times per day (BID), 300 mg two times per day (BID), 400 mg two times per day (BID), 150 mg three times per day (TID), or 250 mg three times per day (TID).

2. The use of claim 1, wherein the UGT inhibitor is selected from canagliflozin, dapagliflozin, mefenamic acid, probenecid, diclofenac, quinidine, fluconazole, and valproic acid.

3. The use of claim 1 or 2, wherein the subject discontinues treatment with the UGT inhibitor at least three weeks before commencing treatment with the medicament.

4. The use of any one of claims 1-3, wherein the subject is female.

5. The use of any one of claims 1-3, wherein the subject is male.

6. The use of any one of claims 1-5, wherein the medicament is for administration of the (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or the pharmaceutically acceptable salt thereof, at a dosage of 200 mg two times per day (BID).

7. The use of any one of claims 1-5, wherein the medicament is for administration of the (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or the pharmaceutically acceptable salt thereof, at a dosage of 150 mg three times per day (TID).

8. The use of any one of claims 1-5, wherein the medicament is for administration of the (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or the pharmaceutically acceptable salt thereof, at a dosage of 250 mg three times per day (TID).

9. The method of claim 8, wherein the subject was not previously treated with (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof.

10. The method of claim 8, wherein the subject had previously been treated with a 150 mg dosage of (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof; *e.g.*, wherein the subject was identified as a non-responder to treatment with a dosage of 150 mg of (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof.

11. The use of any one of claims 1-5, wherein the medicament is for administration of the (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or the pharmaceutically acceptable salt thereof, at a dosage of 300 mg or 400 mg two times per day (BID).

12. The use of claim 11, wherein the dosage is 300 mg BID.

13. The use of claim 12, wherein the subject is a female subject.

14. The use of claim 12 or 13, wherein the medicament is for administration of the (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or the pharmaceutically acceptable salt thereof, at a dosage of 400 mg BID for an initial period of time prior to administration of (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or the pharmaceutically acceptable salt thereof, at a dosage of 300 mg BID.

15. The use of claim 14, wherein the initial period of time is one week.

16. The use of claim 15, wherein the dosage is 400 mg BID.

17. The use of claim 16, wherein the subject is a male subject.

18. The use of any one of claims 1-17, wherein the medicament is formulated for oral administration.

19. The use of any one of claims 1-18, wherein the medicament is for administration in combination with one or more therapeutically effective medicaments.

20. The use of any one of claims 1-19, wherein the disease or condition is trigeminal neuralgia.

21. The use of any one of claims 1-19, wherein the disease or condition is diabetic neuropathy.

22. The use of claim 21, wherein the medicament is for administration of the (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, at a dosage of 250 mg three times per day (TID).

23. The use of any one of claims 1-22, wherein the medicament comprises one or more pharmaceutically acceptable carrier(s), diluent(s), and/or excipient(s).

24. The use of any one of claims 1-23, wherein the (*5R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide or the pharmaceutically acceptable salt thereof is (*5R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide hydrochloride.

25. Use of (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a disease or condition selected from diabetic neuropathy and trigeminal neuralgia, wherein

the subject is receiving treatment with a UGT inhibitor; and

the medicament is for administration of the (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or the pharmaceutically acceptable salt thereof, at a dosage of 50 mg to 350 mg two times per day (BID) or 50 mg to 250 mg three times per day (TID).

26. The use of claim 25, wherein the UGT inhibitor is selected from canagliflozin, dapagliflozin, mefenamic acid, probenecid, diclofenac, quinidine, fluconazole, and valproic acid.

27. The use of claim 25 or 26, wherein the medicament is for administration of the (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or the pharmaceutically acceptable salt thereof, at a dosage at least 30% lower than a dosage for a subject not receiving treatment of a UGT inhibitor.

28. The use of claim 25 or 26, wherein the medicament is for administration of the (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or the pharmaceutically acceptable salt thereof, at a dosage at least 50% lower than a dosage for a subject not receiving treatment of a UGT inhibitor.

29. The use of claim 25 or 26, wherein the medicament is for administration of the (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or the pharmaceutically acceptable salt thereof, at a dosage of 50 mg to 350 mg BID.

30. The use of claim 29, wherein the dosage is 50 mg BID, 100 mg BID, 150 mg BID, 200 mg BID, or 350 mg BID.

31. The use of claim 25 or 26, wherein the medicament is for administration of the (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or the pharmaceutically acceptable salt thereof, at a dosage of 50 mg to 250 mg TID.

32. The use of claim 31, wherein the dosage is 50 mg TID, 75 mg TID, 100 mg TID, 150 mg TID, or 250 mg TID.

33. The use of any one of claims 25-31, the medicament is formulated for oral administration.

34. The use of any one of claims 25-33, wherein the medicament is for administration in combination with one or more therapeutically effective medicaments.

35. The use of any one of claims 25-34, wherein the disease or condition is trigeminal neuralgia.

36. The use of claim 35, wherein the disease or condition is diabetic neuropathy.

37. The use of claim 36, wherein the medicament is for administration of the (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, at a dosage of 50 mg to 250 mg TID.

38. The use of claim 37, wherein the dosage is 50 mg TID, 75 mg TID, 100 mg TID, 150 mg TID, or 250 mg TID.

39. The use of any one of claims 25-38, wherein the medicament comprises one or more pharmaceutically acceptable one or more pharmaceutically acceptable carrier(s), diluent(s), and/or excipient(s).

40. The use of any one of claims 25-39, wherein the (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide or the pharmaceutically acceptable salt thereof is (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide hydrochloride.